MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
|
|
| Suspended | 3 | 220 | Europe, Canada, US, RoW | SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin | Scynexis, Inc., SCYNEXIS, Inc. | Candidiasis, Invasive, Candidemia | 06/24 | 08/24 | | |
NCT04261348: Effects of an Antimicrobial Stewardship (AMS) Program, on the Prevalence of Multidrug-resistant Gram - Negative Pathogens, in an Area of High Consumption of Antibiotics and High Resistance Rates |
|
|
| Recruiting | N/A | 500 | Europe | No intervention | Laikο General Hospital, Athens | Antimicrobial Stewardship Program | 12/21 | 02/22 | | |
